Ardelyx faces high SG&A costs, XPHOZAH reimbursement risks, and weak cash generation with tenapanor sales. Find out exactly ...
The new fundraise comes at the back of several top leadership exits at the venture capital firm after a rift over returns from recent IPO exits.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results